The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer

BACKGROUND: Docetaxel improves overall survival (OS) in castration-resistant prostate cancer (PCa) (CRPC) and metastatic hormone-sensitive PCa (mHSPC). However, not all patients respond due to inherent and/or acquired resistance. There remains an unmet clinical need for a robust predictive test to s...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Caitlin R., Guo, Tianyu, Burke, Edwina, Stankiewicz, Elzbieta, Xu, Lei, Mao, Xueying, Scandura, Glenda, Rajan, Prabhakar, Tipples, Karen, Alifrangis, Constantine, Wimalasingham, Akhila Ganeshi, Galazi, Myria, Crusz, Shanthini, Powles, Thomas, Grey, Alistair, Oliver, Tim, Kudahetti, Sakunthala, Shaw, Greg, Berney, Daniel, Shamash, Jonathan, Lu, Yong-Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885040/
https://www.ncbi.nlm.nih.gov/pubmed/36727071
http://dx.doi.org/10.3389/fonc.2022.1060864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885040/
https://www.ncbi.nlm.nih.gov/pubmed/36727071
http://dx.doi.org/10.3389/fonc.2022.1060864

Ejemplares similares